Clinical Trials Sponsored by Arana Therapeutics Ltd

Total 468 results

Zhejiang University
OriCell Therapeutics Co., Ltd.

Active, not recruiting

A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Multiple Myeloma

China
Meir Medical Center
SpotOn Therapeutics Ltd.

Completed

Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness

Chronic Dizziness

Israel
Hadassah Medical Organization
Vaxil Therapeutics Ltd.

Withdrawn

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Multiple Myeloma | Tumors

Israel
Calliditas Therapeutics AB
Archimedes Development Ltd

Completed

Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

IGA Nephropathy

Sweden
Biohaven Therapeutics Ltd.

Not yet recruiting

Long-term Safety and Tolerability of BHV-7000

Focal Epilepsy
Biohaven Therapeutics Ltd.

Recruiting

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Major Depressive Disorder

United States
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

Neoplasms | Neoplasms by Histologic Type

China
Biohaven Therapeutics Ltd.

Recruiting

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (RISE 2)

Focal Epilepsy

United States
Asia Cell Therapeutics (Shanghai) Co., Ltd.

Not yet recruiting

Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis

Decompensated Liver Cirrhosis
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

NKG2D CAR-NK & Ovarian Cancer

Ovarian Cancer

China
Henan Cancer Hospital
Fundamenta Therapeutics, Ltd.

Not yet recruiting

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

China
Eleusis Therapeutics
Beckley Psytech Pty Ltd

Recruiting

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

Depression | Healthy Volunteers | Major Depressive Disorder

United Kingdom
Peking University
CARsgen Therapeutics Co., Ltd.

Recruiting

Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors

Pancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Peking University
CARsgen Therapeutics Co., Ltd.

Recruiting

Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Fundamenta Therapeutics, Ltd.
Anhui Provincial Hospital

Recruiting

Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

B Cell Malignancy

China
NeoTX Therapeutics Ltd.
Translational Drug Development

Completed

Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NT-NAP-102-1)

Non-small Cell Lung Cancer

United States
Youngene Therapeutics Inc., Ltd.
ProSciento, Inc.

Completed

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

Diabetes Mellitus | Diabetes | Diabetes Mellitus, Type 1 | Type1diabetes

United States
Circadian Therapeutics Ltd
Neuroscience Trials Australia

Completed

First in Human Study of CT-1500 in Healthy Participants

Healthy

Australia
Elevar Therapeutics
Bukwang Pharmaceutical, Co., Ltd.

Completed

Dose-Escalation and Safety Trial of YN968D1

Cancer Patients With Solid Tumors

Korea, Republic of, United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Refractory T-Cell Lymphoma | T Cell Lymphoma in Relapse

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Plasmacytoid; Lymphoma

China
Sunshine Lake Pharma Co., Ltd.
Nicoya Therapeutics (Shanghai) Co., Ltd.

Not yet recruiting

HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia

Chronic Kidney Diseases | Renal Anemia

China
Sunshine Lake Pharma Co., Ltd.
Nicoya Therapeutics (Shanghai) Co., Ltd.

Not yet recruiting

Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.

Hemodialysis | Peritoneal Dialysis

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Ripple Therapeutics Pty Ltd
Novotech (Australia) Pty Limited

Completed

Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy

Diabetic Macular Oedema | Retinal Vein Occlusion With Macular Oedema

Australia, New Zealand, Hong Kong, Canada
Beijing Bio-Targeting Therapeutics Technology Co...

Not yet recruiting

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Solid Tumor

China
Rhizen Pharmaceuticals SA
Incozen Therapeutics Pvt Ltd

Recruiting

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

India
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China
Chongqing University Cancer Hospital
Fundamenta Therapeutics, Ltd.

Not yet recruiting

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Refractory or Relapsed B Cell Lymphoma

China
Qilu Pharmaceutical Co., Ltd.
Cend Therapeutics Inc.

Recruiting

CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer

China
Rare Thyroid Therapeutics International AB
Vitaccess Ltd

Completed

MCT8 Deficiency Caregiver Study

Allan-Herndon-Dudley Syndrome | Monocarboxylate Transporter 8 (MCT8) Deficiency

United Kingdom
Xennials Therapeutics Australia Pty Ltd
Pinotbio, Inc.

Terminated

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Advanced Solid Tumor | High-grade Glioma | Platinum-Resistant Ovarian Cancer | Platinum-Resistant Urothelial Carcinoma

Australia
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

Platinum Resistant Ovarian Cancer

United States
Zhejiang University
Innovative Cellular Therapeutics Co., Ltd.

Unknown

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

Lymphoma

China
Vascular Biogenics Ltd. operating as VBL Therapeutics

Unknown

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Advanced and/or Metastatic Solid Organ Cancer

United States
M. Arkin 1999 Ltd.
Vyne Therapeutics Inc.

Completed

Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

Acne Vulgaris

Israel
Immodulon Therapeutics Ltd
Theradex; HCA International Limited

Completed

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Melanoma

United Kingdom
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers

Biomarker

United Kingdom
Karuna Therapeutics
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia (UNITE-001)

Schizophrenia

China
Nectin Therapeutics Ltd
Merck Sharp & Dohme LLC

Recruiting

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Cancer | Metastatic Cancer | Advanced Solid Tumor | Tumor, Solid | Locally Advanced Solid Tumor

United States, Israel
University of Wisconsin, Madison
Revive Therapeutics, Ltd.

Recruiting

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Substance-Related Disorders | Chemically-Induced Disorders | Substance Use Disorders | Methamphetamine Use Disorder | Stimulant-Use Disorder

United States
Hoffmann-La Roche
BioLineRx, Ltd.; Halozyme Therapeutics

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

United States, United Kingdom, Australia, Korea, Republic of, Taiwan, Israel, Spain
BHB Therapeutics, Ireland LTD
Mérieux NutriSciences Biofortis

Completed

Pharmacokinetics of C6 Ketone Di-ester

Pharmacokinetics

United States
Rhizen Pharmaceuticals SA
Incozen Therapeutics Pvt Ltd

Completed

Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

SARS-CoV-2 Infection

India
Prescient Therapeutics, Ltd.
National Cancer Institute (NCI)

Terminated

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Breast Adenocarcinoma

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

Israel, United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) (GLOBE)

Glioblastoma

United States, Israel, Canada
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

Ulcerative Colitis

Poland, Bulgaria, Hungary

Clinical Trials Sponsored by Arana Therapeutics Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations